Results 51 to 60 of about 8,557 (171)

Editorial: subcutaneous CT‐P13 in Crohn’s disease and ulcerative colitis—small change, big consequences [PDF]

Alimentary Pharmacology & Therapeutics, 2021
LINKED CONTENTThis article is linked to Hanzel et al papers.
Franck Carbonnel, Antoine Meyer
openaire   +2 more sources

Fluorine‐18‐Labeled Nucleotide Analogs Targeting Ecto‐5'‐Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors

Angewandte Chemie, EarlyView.
Fluorine‐18‐labeled CD73 inhibitor [18F]PSB‐19427 enables noninvasive PET mapping of CD73 overexpression in triple‐negative breast (TNBC) and pancreatic cancer. For [18F]PSB‐19427, specific binding in human tumor tissues, favorable biodistribution with prolonged blood retention, robust tumor uptake, and superiority to [18F]FDG in a TNBC model ...
Clemens Dobelmann, Constanze C. Schmies, Georg Wilhelm Rolshoven, Mirko Scortichini, Stefan Wagner, Andreas Isaak, Riham M. Idris, Jennifer Dabel, Lucie Grey, Karolina Losenkova, Susanne Moschütz, Haneen Al Hroub, Antje Keim, Sandra Höppner, Jouko Sandholm, Pia Boström, Maija Hollmén, Norbert Sträter, Sven Hermann, Gennady G. Yegutkin, Kenneth A. Jacobson, Sonja Schelhaas, Christa E. Müller, Anna Junker   +23 more
wiley   +2 more sources

Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial [PDF]

, 2020
Objective. To assess non-inferiority of s.c. to i.v. CT-P13 in RA. Methods. Patients with active RA and inadequate response to MTX participated in this phase I/III double-blind study at 76 sites. Patients received CT-P13 i.v. 3 mg/kg [week (W) 0 and W2]
Bala´ zs, E´ va, Dae Hyun, Yoo, El-Khouri, Elias Chalouhi, Eliseeva, Larisa, Han, Noo Ri, Hrycaj, Paweł, Ivanova, Delina, Jaworski, Janusz, Kasay, Alfredo Berrocal, Kim, Sung Hyun, Lee, Sang Joon, Lee, Seul Gi, Shesternya, Pavel, Shevchuk, Sergii, Stanislavchuk, Mykola, Suh, Jee Hye, Trefler, Jakub, Westhovens, Rene, Wiland, Piotr, Yatsyshyn, Roman, Zawadzki, Marek, Zhdan, Vyacheslav, Ждан, Вячеслав Миколайович   +22 more
core   +1 more source

Patients with Ankylosing Spondylitis Can Maintain Clinical and Functional Improvement after Switching from Infliximab Reference Product to Infliximab Biosimilar (REMSIMA): 12 Months Comparative Open-Label Study

Journal of Clinical Rheumatology and Immunology, 2022
Objective: Efficacy, tolerance, and safety of infliximab biosimilar are the same as infliximab reference product (RP) in the management of ankylosing spondylitis (AS) patients previously were on infliximab RP.
Abdulsatar J. Mathkhor, Ali Altaqi, Abdulnasser Abdullah, Amer Khudhairy   +3 more
doaj   +1 more source

Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease [PDF]

Intestinal Research, 2023
Crohn’s disease (CD) is a relapsing and progressive condition characterized by diarrhea, abdominal pain, weight loss, and hematochezia that results in serious complications such as perforations, fistulas, and abscesses. Various medications, interventions,
Seong-Joon Koh, Sung Noh Hong, Soo-Kyung Park, Byong Duk Ye, Kyeong Ok Kim, Jeong Eun Shin, Yong Sik Yoon, Hong Sub Lee, Sung Hoon Jung, Miyoung Choi, Soo-Young Na, Chang Hwan Choi, Joo Sung Kim,   +13 more
doaj   +1 more source

OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis [PDF]

Journal of Crohn's and Colitis, 2020
Abstract Background Two randomised controlled trials of a novel subcutaneous (SC) formulation of infliximab in patients with active rheumatoid arthritis1 and in patients with active Crohn’s disease (CD) and ulcerative colitis (UC)2 confirmed comparable clinical efficacy and safety of CT-P13 SC with CT-
S Ben-Horin, J Leszczyszyn, R Dudkowiak, A Lahat, B Gawdis-Wojnarska, A Pukitis, M Horynski, K Farkas, J Kierkus, M Kowalski, B D Ye, W Reinisch, S J Lee, S H Kim, M R Kim, Y A Kim, H N Kim, S Schreiber   +17 more
openaire   +1 more source

Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease [PDF]

, 2019
BACKGROUND AND AIMS: To evaluate the clinical outcomes in patients with IBD after switching from Remicade® to CT-P13 in comparison with patients who maintain Remicade®. METHODS: Patients under Remicade® who were in clinical remission with standard dosage
Alcaide, N., Amo, V., Arguelles, F., Barreiro de Acosta, Manuel, Benitez, J. M., Bermejo, F., Bernardo, D., Bujanda, L., Calvet, X., Carbajo, A. Y., Chaparro, M., De Castro Parga, María Luisa, De Castro, M. L., Garre, A., Gisbert, J. P., Gomollon, F., Gutierrez, A., Iborra, M., Jimenez, I., Kolle, L., Leo, E., Lorente, R., Manosa, M., Morell, A., Moron, J. M. V., Ramirez, E., Riestra, S., Rivero, M., Rodriguez, E., Rojas-Feria, M., Van Domselaar, M., Veloz, M. F. G.   +31 more
core   +4 more sources

Position Paper Português Sobre o Uso de Biossimilares na Psoríase [PDF]

, 2016
info:eu-repo/semantics ...
Ferreira, A., Ferreira, P., Filipe, P., Henriques, M., Leite, L., Magina, S., Marques-Pinto, G., Massa, A., Oliveira, H., Selores, M., Sousa-Basto, A., Tavares-Bello, R., Torres, T., Varela, P.   +13 more
core   +2 more sources

Comparative effectiveness of the biosimilar CT-P13

Journal of Comparative Effectiveness Research, 2017
The first biosimilar infliximab, CT-P13 (infliximab-dyyb) has been used for the treatment of inflammatory diseases for 4 years. CT-P13 has highly similar efficacy and safety profiles with a lower price than the originator infliximab and has been approved in 81 countries.
openaire   +2 more sources

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study [PDF]

Annals of the Rheumatic Diseases, 2017
To investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS).This open-label extension study recruited patients with AS who completed a 54-week, randomised controlled study comparing CT-P13 with RP (PLANETAS). CT-P13 (5 mg/kg)
Park, Won, Yoo, Dae Hyun, Miranda, Pedro, Brzosko, Marek, Wiland, Piotr, Gutierrez-Ureña, Sergio, Mikazane, Helena, Lee, Yeon Ah, Smiyan, Svitlana, Lim, Mie Jin, Kadinov, Vladimir, Abud-Mendoza, Carlos, Kim, Houng, Lee, Sang Joon, Bae, Yunju, Kim, Suyeon, Braun, Jürgen   +16 more
openaire   +3 more sources